Health and Wealth, en podd från BioStock om investeringar i life science BioStock

Søren Lemonius, founder and managing partner at Sunstone Life Science Ventures, shares the story of how he and his team initiated the Danish VC firm’s investment strategy that has lead to a number of very successful exits – and to some very costly losses. He also reveals why early-stage deals often yield the best returns (”because you’re selling a multiple of a dream”), explains why venture capital thrives in times of crisis and shares the one major reason for why some investments never materialise. We ponder the concept of longevity and find out what Søren considers to be the next hot areas to invest in, why IPOs are not a prefered exit option for Sunstone’s investments and why venture capital firms usually thrive in times of crisis.
Hosted on Acast. See acast.com/privacy for more information.

When Johan Kördel, a seasoned investor and managing partner at Swedish venture capital firm Sound Bioventures, suddenly woke up during an earthquake, he knew exactly what to do, yet he did nothing. Luckily, he lived to tell us the earthquake story, and much more! In this episode of Health & Wealth we talk about the dangers of doing nothing as a leader, the importance of risk management and why a portfolio approach is key when you invest in drug development. We also dive into his best investments (and a truly eye-popping exit!), learn about raising a billion SEK fund during a pandemic (hint: you need skin in the game!) and discuss why some disease areas are not considered lucrative, and why being decent is very cool.
Hosted on Acast. See acast.com/privacy for more information.

Drivkraften för Philip Siberg, vd på Senzime, är att göra skillnad i hundra miljoner människors liv. Hör honom berätta om varför han bestämt sig för att arbeta för hållbarhet, mänskliga rättigheter och om vikten att sträva mot en vision som är värd att berätta för barnbarnen om!
Hosted on Acast. See acast.com/privacy for more information.

When developing new therapies or medicines, there are many hurdles along the way to reaching the market. If you do, that is. Failure is lurking at every step. A drug candidate must be safe and have efficacy in patients without severe side effects. The risks are significant and so are the costs, but if a project is successful the reward could be enormous. 
So, how to assess the risks involved correctly? 
In this episode of Health & Wealth Jesper Prior Larsen from Aixial Group, leading experts at clinical trials, walks us through some of the things you need to be aware of before investing in life science.

Hosted on Acast. See acast.com/privacy for more information.

Vad är mest irriterande med svenskars sätt att kommunicera? I avsnitt 8 av Health & Wealth konfronterar vi dansk-svenskt samarbete, kulturkrockar och visioner som skulle besannas, bara vi stod ut med varandra. Gäst är Søren Bregenholt, vd för Alligator Bioscience!
(Avsnittet sker på engelska)

Hosted on Acast. See acast.com/privacy for more information.

Svåra samtal ingår i jobbet som vd. Hur har man dem ansvarsfullt, tydligt och utan att lämna medarbetare med känslan av misslyckande?
I avsnitt sju av Health & Wealth pratar vi med Jens Lindberg, vd för Medivir om ledarskap, gruppens styrka och om framtiden för patienter med levercancer.

Hosted on Acast. See acast.com/privacy for more information.